Literature DB >> 26941861

Semi-Quantitative Analysis of Post-Transarterial Radioembolization (90)Y Microsphere Positron Emission Tomography Combined with Computed Tomography (PET/CT) Images in Advanced Liver Malignancy: Comparison With (99m)Tc Macroaggregated Albumin (MAA) Single Photon Emission Computed Tomography (SPECT).

Seunghong Rhee1, Sungeun Kim1, Jaehyuk Cho1, Jukyung Park1, Jae Seon Eo2, Soyeon Park2, Eunsub Lee2, Yun Hwan Kim3, Jae-Gol Choe1.   

Abstract

OBJECTIVES: The purpose of this study is to evaluate the correlation between pretreatment planning technetium-99m ((99m)Tc) macroaggregated albumin (MAA) SPECT images and posttreatment transarterial radioembolization (TARE) yttirum-90 ((90)Y) PET/CT images by comparing the ratios of tumor-to-normal liver counts.
METHODS: Fifty-two patients with advanced hepatic malignancy who underwent (90)Y microsphere radioembolization from January 2010 to December 2012 were retrospectively reviewed. Patients had undergone (99m)Tc MAA intraarterial injection SPECT for a pretreatment evaluation of microsphere distribution and therapy planning. After the administration of (90)Y microspheres, the patients underwent posttreatment (90)Y PET/CT within 24 h. For semiquantitative analysis, the tumor-to-normal uptake ratios in (90)Y PET/CT (TNR-yp) and (99m)Tc MAA SPECT (TNR-ms) as well as the tumor volumes measured in angiographic CT were obtained and analyzed. The relationship of TNR-yp and TNR-ms was evaluated by Spearman's rank correlation and Wilcoxon's matched pairs test.
RESULTS: In a total of 79 lesions of 52 patients, the distribution of microspheres was well demonstrated in both the SPECT and PET/CT images. A good correlation was observed of between TNR-ms and TNR-yp (rho value = 0.648, p < 0.001). The TNR-yp (median 2.78, interquartile range 2.43) tend to show significantly higher values than TNR-ms (median 2.49, interquartile range of 1.55) (p = 0.012). The TNR-yp showed weak correlation with tumor volume (rho = 0.230, p = 0.041).
CONCLUSIONS: The (99m)Tc MAA SPECT showed a good correlation with (90)Y PET/CT in TNR values, suggesting that (99m)Tc MAA can be used as an adequate pretreatment evaluation method. However, the (99m)Tc MAA SPECT image consistently shows lower TNR values compared to (90)Y PET/CT, which means the possibility of underestimation of tumorous uptake in the partition dosimetry model using (99m)Tc MAA SPECT. Considering that (99m)Tc MAA is the only clinically available surrogate marker for distribution of microsphere, we recommend measurement of tumorous uptake using (90)Y PET/CT should be included routinely in the posttherapeutic evaluation.

Entities:  

Keywords:  Liver malignancy; Microsphere; PET scan; Radioembolization; Single-photon emission computerized tomography; Tc-99m-MAA; Y-90

Year:  2015        PMID: 26941861      PMCID: PMC4762868          DOI: 10.1007/s13139-015-0366-9

Source DB:  PubMed          Journal:  Nucl Med Mol Imaging        ISSN: 1869-3474


  31 in total

1.  Feasibility of 90Y TOF PET-based dosimetry in liver metastasis therapy using SIR-Spheres.

Authors:  Renaud Lhommel; Larry van Elmbt; Pierre Goffette; Marc Van den Eynde; François Jamar; Stanislas Pauwels; Stephan Walrand
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-04-27       Impact factor: 9.236

2.  Yttrium-90 microsphere-selective internal radiation therapy with chemotherapy (chemo-SIRT) for colorectal cancer liver metastases: an in vivo double-arm-controlled phase II trial.

Authors:  Seza A Gulec; Kenneth Pennington; James Wheeler; Tushar C Barot; Rekha R Suthar; Michael Hall; Douglas Schwartzentruber
Journal:  Am J Clin Oncol       Date:  2013-10       Impact factor: 2.339

3.  99mTc-macroaggregated albumin poorly predicts the intrahepatic distribution of 90Y resin microspheres in hepatic radioembolization.

Authors:  Maurits Wondergem; Maarten L J Smits; Mattijs Elschot; Hugo W A M de Jong; Helena M Verkooijen; Maurice A A J van den Bosch; Johannes F W Nijsen; Marnix G E H Lam
Journal:  J Nucl Med       Date:  2013-06-07       Impact factor: 10.057

Review 4.  Radioembolization for hepatocellular carcinoma.

Authors:  Bruno Sangro; Mercedes Iñarrairaegui; Jose I Bilbao
Journal:  J Hepatol       Date:  2011-08-02       Impact factor: 25.083

5.  Tumour-to-normal uptake ratio of 90Y microspheres in hepatic cancer assessed with 99Tcm macroaggregated albumin.

Authors:  S Ho; W Y Lau; T W Leung; M Chan; K W Chan; W Y Lee; P J Johnson; A K Li
Journal:  Br J Radiol       Date:  1997-08       Impact factor: 3.039

6.  Histopathologic correlation of hepatocellular carcinoma after transcatheter arterial chemoembolization with polyvinyl alcohol particle of various sizes.

Authors:  Ming-Yuan Lee; Vincent P Chuang; Chao-Jung Wei; Tsung-Yen Cheng; Ming-Tsu Cherng
Journal:  Eur J Radiol       Date:  2011-05-31       Impact factor: 3.528

7.  Comparison of positron emission tomography and bremsstrahlung imaging to detect particle distribution in patients undergoing yttrium-90 radioembolization for large hepatocellular carcinomas or associated portal vein thrombosis.

Authors:  Siddharth A Padia; Adam Alessio; Sharon W Kwan; David H Lewis; Sandeep Vaidya; Satoshi Minoshima
Journal:  J Vasc Interv Radiol       Date:  2013-06-20       Impact factor: 3.464

8.  Diagnostic pharmaco-scintigraphy with hepatic intra-arterial technetium-99m macroaggregated albumin in the determination of tumour to non-tumour uptake ratio in hepatocellular carcinoma.

Authors:  W Y Lau; T W Leung; S Ho; M Chan; N W Leung; J Lin; C Metreweli; A K Li
Journal:  Br J Radiol       Date:  1994-02       Impact factor: 3.039

9.  Quantitative analysis of 90Y Bremsstrahlung SPECT-CT images for application to 3D patient-specific dosimetry.

Authors:  Cinzia Fabbri; Graziella Sarti; Marta Cremonesi; Mahila Ferrari; Amalia Di Dia; Monica Agostini; Francesca Botta; Giovanni Paganelli
Journal:  Cancer Biother Radiopharm       Date:  2009-02       Impact factor: 3.099

10.  Safety and efficacy of Y-90 microsphere treatment in patients with primary and metastatic liver cancer: the tumor selectivity of the treatment as a function of tumor to liver flow ratio.

Authors:  Seza A Gulec; Geraldine Mesoloras; William A Dezarn; Patrick McNeillie; Andrew S Kennedy
Journal:  J Transl Med       Date:  2007-03-14       Impact factor: 5.531

View more
  7 in total

1.  Personalized Dosimetry for Liver Cancer Y-90 Radioembolization Using Computational Fluid Dynamics and Monte Carlo Simulation.

Authors:  Emilie Roncali; Amirtahà Taebi; Cameron Foster; Catherine Tram Vu
Journal:  Ann Biomed Eng       Date:  2020-01-31       Impact factor: 3.934

Review 2.  KSNM 60 in General Nuclear Medicine: the Old Dream Comes True.

Authors:  Won Woo Lee; Jin-Sook Ryu
Journal:  Nucl Med Mol Imaging       Date:  2022-01-28

Review 3.  KSNM60 in Non-thyroidal Radionuclide Therapy: Leaping into the Future.

Authors:  Byung Hyun Byun; Myoung Hyoun Kim; Yeon-Hee Han; Hwan-Jeong Jeong
Journal:  Nucl Med Mol Imaging       Date:  2021-08-23

4.  Predictive SIRT dosimetry based on a territorial model.

Authors:  Nadine Spahr; Philipp Schilling; Smita Thoduka; Nasreddin Abolmaali; Andrea Schenk
Journal:  EJNMMI Phys       Date:  2017-10-31

5.  Diagnostic and prognostic value of 99mTc-MAA SPECT/CT for treatment planning of 90Y-resin microsphere radioembolization for hepatocellular carcinoma: comparison with planar image.

Authors:  Mai Hong Son; Le Ngoc Ha; Mai Hong Bang; Sungwoo Bae; Dinh Truong Giang; Nguyen Tien Thinh; Jin Chul Paeng
Journal:  Sci Rep       Date:  2021-02-05       Impact factor: 4.379

6.  Correlation of C-arm CT acquired parenchymal blood volume (PBV) with 99mTc-macroaggregated albumin (MAA) SPECT/CT for radioembolization work-up.

Authors:  Matthias Weissinger; Jonas Vogel; Jürgen Kupferschläger; Helmut Dittmann; Salvador Guillermo Castaneda Vega; Ulrich Grosse; Christoph Artzner; Konstantin Nikolaou; Christian la Fougere; Gerd Grözinger
Journal:  PLoS One       Date:  2020-12-30       Impact factor: 3.240

Review 7.  Personalised Dosimetry in Radioembolisation for HCC: Impact on Clinical Outcome and on Trial Design.

Authors:  Etienne Garin; Xavier Palard; Yan Rolland
Journal:  Cancers (Basel)       Date:  2020-06-12       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.